Log In
BCIQ
Print this Print this
 

sodium zirconium cyclosilicate (ZS-9)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionInorganic crystal form of zirconium silicate designed to trap potassium ions over other ions throughout the GI tract
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentRegistration
Standard Indication Hematology (unspecified)
Indication DetailsTreat hyperkalemia
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,700.0M

$2,700.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/16/2015

$2,700.0M

$2,700.0M

0

Get a free BioCentury trial today